+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID03057860

German National Clinical Registry for Moderate-to-Severe Atopic Dermatitis Treatment and Care

Led by Technische Universität Dresden · Updated on 2022-05-09

2800

Participants Needed

3

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Moderate-to-severe atopic dermatitis AD affects many children, adolescents, and adults, with a higher prevalence in younger populations. This research focuses on understanding how systemic treatments and topical therapies work in real-world settings, especially for those whose condition is not controlled by topical treatments alone. The study aims to fill gaps in knowledge about long-term treatment effectiveness and patient outcomes, particularly in children and adolescents, to support better healthcare decisions and improve care transitions from adolescence to adulthood. Participants in this observational study will not receive any study-specific treatment. Instead, they will be followed for at least 24 months with regular visits to document their health status, treatment plans, and patient experiences. Visits are scheduled at baseline, 3 months, 6 months, and then every 3 or 6 months depending on treatment changes. Some participants may optionally provide biological samples for molecular analysis. The study collects detailed clinical and patient-reported data to track disease progression and treatment effects over time. Throughout the study, participants will complete questionnaires and undergo evaluations to assess disease severity, symptoms, quality of life, treatment satisfaction, and flare-ups. Data is collected electronically and securely stored. Researchers will review changes in the objective SCORAD score over two years as the primary outcome. Secondary outcomes include patient-reported eczema measures, symptom severity, quality of life, and flare control. This long-term monitoring helps provide valuable insights into the course and management of moderate-to-severe AD.

CONDITIONS

Brief Title

TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis

Research Team

J

Jochen Schmitt, Prof.Dr.

E

Eva Haufe, Dr.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here